Mirava Bio is a Swiss BioCommercial Partner enabling emerging biotechs to bring rare disease & gene therapies to Europe, the Middle East & Eurasia. We define optimal go-to-market strategies and execute via a plug-and-play licensed ready platform, minimizing risk while partners retain control.
Products, services, technology
Mirava Bio supports biotechs from strategy to execution: defining tailored go-to-market plans, navigating market access & regulatory pathways, enabling early access sales, and operating as a fully licensed virtual affiliate across EMEE to deliver rare disease therapies to patients.
- https://www.miravabio.com/
- +41 79 545 04 48
- Send an email
- Vincent Lévêque
Some insights
Mirava Bio aims to be the leading partner for rare disease drug companies, empowering them to expand geographically while minimizing the financial risk and creating value.
We strive to bring highly innovative therapies to rare disease patients and making a meaningful impact on global health.
I’m proud of Mirava Bio because we bridge innovation and patients: enabling biotechs to bring life-changing rare disease therapies to underserved regions. We reduce risk, speed access, and help ensure that no patient is left without hope due to geography or cost.
Role models in rare disease inspire us to put patients first, act with courage, and lead with integrity. They show that innovation and access can go hand in hand, reminding us that our industry’s true measure of success is the lives we change, not just the markets we enter.
Our team combines deep expertise in rare diseases, ATMP commercialization, finance, and market access across EMEE. We excel at strategy and execution. Looking ahead, we aim to strengthen medical affairs, regulatory, and digital capabilities to scale our impact further.
Commited, passionate, entrepreneur with a sense of purpose.
The Swiss biotech ecosystem can support us by connecting Mirava Bio with emerging biotechs lacking an EMEA footprint, facilitating introductions to local partners, and offering platforms, events, forums, and training, where we can showcase our model and build collaborations.
We seek to connect with emerging biotechs developing rare disease and gene therapies, Swiss investors, patient advocacy groups, regulatory and market access experts, as well as ecosystem partners who can help us accelerate entry and impact across Europe, the Middle East & Eurasia.
